Is Alunbrig Right for Me? Your health care provider will consider what type of lung cancer you have and whether it has spread to help choose the right treatment for you. Alunbrig is used for NSCLC ...

Melanomas caused by sun exposure have been matched with targeted treatments and immunotherapies, in many cases dramatically extending patients' lives. However, there are other kinds of melanoma not ...

If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC). Prior ...

The latest results from the CROWN study didn’t just confirm that lorlatinib (Lorbrena) works well; this study revealed something almost unheard of in advanced lung cancer. At the ASCO 2026 meeting, ...

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who ...

Logan Terry, who has stage 4 ALK-positive lung cancer, encouraged patients with cancer to keep living fully after diagnosis and not be defined by fear or bitterness. Patients who are newly diagnosed ...

CHICAGO -- Five-year results from a phase III trial had experts gushing over lorlatinib's (Lorbrena) progression-free survival (PFS) benefit in ALK-positive non-small cell lung cancer (NSCLC). In the ...

Matthew Herper covers medical innovation — both its promise and its perils. The biotechnology firm Nuvalent said Monday that its drug for a genetically defined type of lung cancer shrank tumors in ...